Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

18F-Fluoroestradiol.

Lavanya Sundararajan1, Hannah M Linden, Jeanne M Link

  • 1Department of Medicine, University of Washington and Seattle Cancer Care Alliance, Seattle, WA, USA.

Seminars in Nuclear Medicine
|October 9, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Practice Patterns in Diagnosis and First-Line Treatment in Metastatic Breast Cancer.

The breast journal·2026
Same author

Prospective exploratory pilot study of 18 F-FMISO PET/CT for assessing tumor hypoxia in soft tissue sarcomas.

Cancer imaging : the official publication of the International Cancer Imaging Society·2026
Same author

A Call for High-Level Evidence Before Routine Implementation of Posttreatment SPECT.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Response to the Comment on "Negative 18 F-FES PET/CT Despite Estrogen Receptor Positivity By Immunohistochemistry."

Clinical nuclear medicine·2026
Same author

Differential Response to <sup>177</sup>Lu-PSMA-617 in Patients with Tumor Suppressor Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

[ 18 F]Fluoroestradiol Uptake in Benign Nodular Sclerosing Adenosis of the Breast.

Clinical nuclear medicine·2026

Positron emission tomography (PET) with (18)F-16alpha-17beta-fluoroestradiol (FES) shows promise for imaging estrogen receptor (ER) expression in breast cancer. FES-PET may help predict response to endocrine therapy and overcome limitations of traditional biopsy assays.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiochemistry

Background:

  • Estrogen receptor (ER) expression is crucial for breast cancer behavior and response to endocrine therapies.
  • Current methods for assessing ER expression rely on biopsy tissue, which can be challenging in advanced disease and prone to sampling errors.
  • Novel imaging agents are needed to accurately assess ER status non-invasively.

Purpose of the Study:

  • To review the role of ER in breast cancer therapy.
  • To discuss the development, properties, and validation of (18)F-16alpha-17beta-fluoroestradiol (FES) as an ER imaging agent for positron emission tomography (PET).
  • To highlight the potential clinical utility of FES-PET in breast cancer management.

Main Methods:

  • Review of literature on ER biology, FES structure, synthesis, kinetics, safety, and dosimetry.

Related Experiment Videos

  • Analysis of validation studies for FES-PET.
  • Examination of early clinical data on FES-PET for tumor localization and prediction of endocrine therapy response.

    • Main Results:

    • FES is a successful ER imaging agent for PET.
    • FES-PET demonstrates accuracy in localizing ER-expressing tumors.
    • Preliminary data suggest FES-PET can predict response to breast cancer endocrine therapy.

    Conclusions:

    • FES-PET shows significant potential for clinical utility in breast cancer management.
    • Further validation and clinical trials are warranted to establish FES-PET's role under regulatory oversight.
    • FES-PET may offer a non-invasive method to assess ER status and guide treatment decisions.